Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (77)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Brandt, A.
Right arrow Articles by Lehmann-Horn, F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Brandt, A.
Right arrow Articles by Lehmann-Horn, F.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Human Molecular Genetics, Vol 8, 2055-2062, Copyright © 1999 by Oxford University Press

ARTICLES

Screening of the ryanodine receptor gene in 105 malignant hyperthermia families: novel mutations and concordance with the in vitro contracture test

A Brandt, L Schleithoff, K Jurkat-Rott, W Klingler, C Baur and F Lehmann-Horn
Department of Applied Physiology and.

Malignant hyperthermia (MH) in man is an autosomal dominant disorder of skeletal muscle Ca(2+)-regulation. During anesthesia in predisposed individuals, it is triggered by volatile anesthetics and depolarizing muscle relaxants. In >50% of the families, MH susceptibility is linked to the gene encoding the skeletal muscle ryanodine receptor (RYR1), the calcium release channel of the sarcoplasmic reticulum, on chromosome 19q12-13.2. To date, 21 RYR1 mutations have been identified in a number of pedigrees. Four of them are also associated with central core disease (CCD), a congenital myopathy. Screening for these 21 mutations in 105 MH families including 10 CCD families phenotyped by the in vitro contracture test (IVCT) according to the European protocol revealed the following approximate distribution: 9% Arg-614-Cys, 1% Arg-614-Leu, 1% Arg-2163-Cys, 1% Val-2168-Met, 3% Thr-2206-Met and 7% Gly-2434-Arg. In one CCD family, the disease was caused by a recently reported MH mutation, Arg-2454-His. Two novel mutations, Thr-2206-Arg and Arg-2454- Cys were detected, each in a single pedigree. In the 109 individuals of the 25 families with RYR1 mutations cosegregation between genetic result and IVCT was almost perfect, only three genotypes were discordant with the IVCT phenotypes, suggesting a true sensitivity of 98.5% and a specificity of minimally 81.8% for this test. Screening of the transmembraneous region of RYR1 did not yield a new mutation confirming the cytosolic portion of the protein to be of main functional importance for disease pathogenesis.
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 J. Mol. Diagn.Home page
W. Creighton, R. Virmani, R. Kutys, and A. Burke
Identification of Novel Missense Mutations of Cardiac Ryanodine Receptor Gene in Exercise-Induced Sudden Death at Autopsy
J. Mol. Diagn., February 1, 2006; 8(1): 62 - 67.
[Abstract] [Full Text] [PDF]

Home page
 Anesth. Analg.Home page
H.-M. Yeh, M.-C. Tsai, Y.-N. Su, R.-C. Shen, J.-J. Hwang, W.-Z. Sun, and L.-P. Lai
Denaturing High Performance Liquid Chromatography Screening of Ryanodine Receptor Type 1 Gene in Patients with Malignant Hyperthermia in Taiwan and Identification of a Novel Mutation (Y522C)
Anesth. Analg., November 1, 2005; 101(5): 1401 - 1406.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
A. A. Voss, J. Lango, M. Ernst-Russell, D. Morin, and I. N. Pessah
Identification of Hyperreactive Cysteines within Ryanodine Receptor Type 1 by Mass Spectrometry
J. Biol. Chem., August 13, 2004; 279(33): 34514 - 34520.
[Abstract] [Full Text] [PDF]

Home page
 J. Med. Genet.Home page
S Shepherd, F Ellis, J Halsall, P Hopkins, and R Robinson
RYR1 mutations in UK central core disease patients: more than just the C-terminal transmembrane region of the RYR1 gene
J. Med. Genet., March 1, 2004; 41(3): e33 - 33.
[Full Text] [PDF]

Home page
 Arch NeurolHome page
S. Guis, D. Figarella-Branger, N. Monnier, D. Bendahan, G. Kozak-Ribbens, J.-P. Mattei, J. Lunardi, P. J. Cozzone, and J.-F. Pellissier
Multiminicore Disease in a Family Susceptible to Malignant Hyperthermia: Histology, In Vitro Contracture Tests, and Genetic Characterization
Arch Neurol, January 1, 2004; 61(1): 106 - 113.
[Abstract] [Full Text] [PDF]

Home page
 Circ. Res.Home page
P.D. Allen
Not All Sudden Death Is the Same
Circ. Res., September 19, 2003; 93(6): 484 - 486.
[Full Text] [PDF]

Home page
 J. Physiol.Home page
A. M Duke, P. M Hopkins, and D. S Steele
Effects of Mg2+ and SR luminal Ca2+ on caffeine-induced Ca2+ release in skeletal muscle from humans susceptible to malignant hyperthermia
J. Physiol., October 1, 2002; 544(1): 85 - 95.
[Abstract] [Full Text] [PDF]

Home page
 Circ. Res.Home page
P.D. Allen
Leaky "Feet" and Sudden Death
Circ. Res., August 9, 2002; 91(3): 181 - 182.
[Full Text] [PDF]

Home page
 Hum Mol GenetHome page
N. Monnier, N. B. Romero, J. Lerale, P. Landrieu, Y. Nivoche, M. Fardeau, and J. Lunardi
Familial and sporadic forms of central core disease are associated with mutations in the C-terminal domain of the skeletal muscle ryanodine receptor
Hum. Mol. Genet., October 1, 2001; 10(22): 2581 - 2592.
[Abstract] [Full Text] [PDF]

Home page
 Br J AnaesthHome page
A. Urwyler, T. Deufel, T. McCarthy, and S. West
Guidelines for molecular genetic detection of susceptibility to malignant hyperthermia{{dagger}}
Br. J. Anaesth., February 1, 2001; 86(2): 283 - 287.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
P. C. Scacheri, E. P. Hoffman, J. D. Fratkin, C. Semino-Mora, A. Senchak, M. R. Davis, N. G. Laing, V. Vedanarayanan, and S. H. Subramony
A novel ryanodine receptor gene mutation causing both cores and rods in congenital myopathy
Neurology, December 12, 2000; 55(11): 1689 - 1696.
[Abstract] [Full Text] [PDF]

Home page
 Hum Mol GenetHome page
N. Monnier, N. B. Romero, J. Lerale, Y. Nivoche, D. Qi, D. H. MacLennan, M. Fardeau, and J. Lunardi
An autosomal dominant congenital myopathy with cores and rods is associated with a neomutation in the RYR1 gene encoding the skeletal muscle ryanodine receptor
Hum. Mol. Genet., November 1, 2000; 9(18): 2599 - 2608.
[Abstract] [Full Text] [PDF]

Home page
 Br J AnaesthHome page
Baur, W. Klingler, K. Jurkat-Rott, G. Froeba, E. Schoch, T. Marx, M. Georgieff, and F. Lehmann-Horn
Xenon does not induce contracture in human malignant hyperthermia muscle{dagger}
Br. J. Anaesth., November 1, 2000; 85(5): 712 - 716.
[Abstract] [Full Text] [PDF]

Home page
 Physiol. Rev.Home page
M. W. Berchtold, H. Brinkmeier, and M. Muntener
Calcium Ion in Skeletal Muscle: Its Crucial Role for Muscle Function, Plasticity, and Disease
Physiol Rev, July 1, 2000; 80(3): 1215 - 1265.
[Abstract] [Full Text] [PDF]

Home page
 Hum Mol GenetHome page
R. L. Brown, A. N. Pollock, K. G. Couchman, M. Hodges, D. O. Hutchinson, R. Waaka, P. Lynch, T. V. McCarthy, and K. M. Stowell
A novel ryanodine receptor mutation and genotype-phenotype correlation in a large malignant hyperthermia New Zealand Maori pedigree
Hum. Mol. Genet., June 12, 2000; 9(10): 1515 - 1524.
[Abstract] [Full Text] [PDF]

Home page
 Anesth. Analg.Home page
C. P. Baur, L. Bellon, P. Felleiter, M. Fiege, R. Fricker, K. Glahn, J. J. A. Heffron, A. Herrmann-Frank, K. Jurkat-Rott, W. Klingler, et al.
A Multicenter Study of 4-Chloro-m-cresol for Diagnosing Malignant Hyperthermia Susceptibility
Anesth. Analg., January 1, 2000; 90(1): 200 - 200.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.